SRDX (Surmodics) Ending Cash Position: $26.3 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
View Full Analysis

What is Surmodics Ending Cash Position?

Surmodics SRDX -0.01% 51 Ending Cash Position is $26.3 Mil as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100.

Surmodics's Ending Cash Position for the quarter that ended in Jun. 2025 was $26.3 Mil.

Surmodics's quarterly Ending Cash Position declined from Dec. 2024 ($30.1 Mil) to Mar. 2025 ($29.2 Mil) and declined from Mar. 2025 ($29.2 Mil) to Jun. 2025 ($26.3 Mil).

Surmodics's annual Ending Cash Position increased from Sep. 2022 ($19.0 Mil) to Sep. 2023 ($41.4 Mil) but then declined from Sep. 2023 ($41.4 Mil) to Sep. 2024 ($36.1 Mil).

Surmodics Ending Cash Position Related Terms

Surmodics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Surmodics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Ending Cash Position Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.79 31.15 19.00 41.42 36.12

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.30 36.12 30.15 29.18 26.28
SRDX
51GF Score
Surmodics Inc SRDX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Surmodics's Ending Cash Position for the fiscal year that ended in Sep. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=41.419+-5.304
=36.1

Surmodics's Ending Cash Position for the quarter that ended in Jun. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=29.183+-2.902
=26.3

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $26.3 Mil mean?
Surmodics (SRDX) has a Ending Cash Position of $26.3 Mil as of Jun. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Surmodics and its competitors.
Is Surmodics' Ending Cash Position too high?
Surmodics' current Ending Cash Position is $26.3 Mil. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Ending Cash Position compare to CBLL and OFIX?
Surmodics' Ending Cash Position of $26.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Surmodics and its competitors. Surmodics's current Ending Cash Position is $26.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Ending Cash Position of $26.3 Mil. The current Ending Cash Position is $26.3 Mil. Surmodics' overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Surmodics (SRDX), the current Ending Cash Position is $26.3 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price